Top

Published in:

25-05-2023 | Metastasis | Original Article

The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma

Authors: Manato Ohsawa, Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada

Published in: Surgery Today | Issue 1/2024

Abstract

Purpose

Various treatments are used for early postoperative recurrence of esophageal cancer, which has a poor prognosis. We evaluated the differences in outcomes and prognoses of each treatment modality between patients with early and late recurrence.

Methods

Early and late recurrence were defined as recurrence within and after six postoperative months, respectively. Of the 351 patients with esophageal squamous cell carcinoma who underwent R0 resection esophagectomy, 98 experienced postoperative recurrence (early recurrence, n = 41; late recurrence, n = 57). We evaluated the characteristics of patients with early and late recurrence and compared their treatment responses and prognoses.

Results

Regarding treatment responses for chemotherapy or immunotherapy, the objective response rate was not significantly different between the early- and late-recurrence groups. For chemoradiotherapy, the objective response rate was significantly lower in the early-recurrence group than in the late-recurrence group. The overall survival was significantly worse in the early-recurrence group than in the late-recurrence group. An analysis by treatment type showed that the early-recurrence group had significantly worse overall survival for chemoradiotherapy, surgery, and radiotherapy than the late-recurrence group.

Conclusions

Patients with early recurrence had particularly poor prognoses with worse post recurrence treatment efficacy than those with late recurrence. The differences in the treatment efficacy and prognosis were particularly pronounced for local therapy.

Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in esophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545–53.PubMedCrossRef

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.PubMedCrossRef

Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.PubMedCrossRef

Dresner SM, Griffin SM. Pattern of recurrence following radicaloesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–33.PubMedCrossRef

Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann Surg Oncol. 2015;22:S1292–300.PubMedCrossRef

Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:3353–61.PubMedCrossRef

Abate E, DeMeester SR, Zehetner J, Oezcelik A, Ayazi S, Costales J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.PubMedCrossRef

Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.PubMedCrossRef

Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616–23.PubMedCrossRef

10.

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.PubMedCrossRef

11.

Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31:1107–14.PubMedCrossRef

12.

Smit JK, Pultrum BB, van Dullemen HM, Van Dam GM, Groen H, Plukker JT. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. Am J Surg. 2010;200:446–53.PubMedCrossRef

13.

Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15:558–65.PubMedCrossRef

14.

Skinner DB, Little AG, Ferguson MK, Soriano A, Staszak VM. Selection of operation for esophageal cancer based on staging. Ann Surg. 1986;204:391–401.PubMedPubMedCentralCrossRef

15.

Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.PubMedPubMedCentralCrossRef

16.

Matthews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg. 1986;73:621–3.PubMedCrossRef

17.

Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143–8.PubMedCrossRef

18.

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRef

19.

Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–25.PubMedCrossRef

20.

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.PubMedCrossRef

21.

Yoshida N, Baba Y, Shigaki H, Harada K, Iwatsuki M, Sakamoto Y, et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. Int J Clin Oncol. 2016;21:1071–8.PubMedCrossRef

22.

Sugiyama M, Morita M, Yoshida R, Ando K, Egashira A, Takefumi O, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.PubMedCrossRef

23.

Takashima A, Shirao K, Hirashima Y, Takahari D, Okita N, Akatsuka S, et al. Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus. 2008;21:607–11.PubMedCrossRef

24.

Zhu ZJ, Hu Y, Zhao YF, Chen XZ, Chen LQ, Chen YT. Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91:1502–8.PubMedCrossRef

25.

Stiles BM, Salzler GG, Nasar A, Paul S, Lee PC, Port JL, et al. Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomy. Eur J Cardiothorac Surg. 2015;48:455–60.PubMedCrossRef

26.

Davies AR, Pillai A, Sinha P, Sandhu H, Adeniran A, Mattsson F, et al. Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol. 2014;109:459–64.PubMedCrossRef

27.

Kosugi S, Kanda T, Yajima K, Ishikawa T, Hatakeyama K. Risk factors that influence early death due to cancer recurrence after extended radical esophagectomy with three-field lymph node dissection. Ann Surg Oncol. 2011;18:2961–7.PubMedCrossRef

28.

Kurogochi T, Honda M, Takahashi K, Okamura A, Imamura Y, Yamashita K, et al. Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer. Surg Today. 2022;52:660–7.PubMedCrossRef

29.

Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, et al. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer. 2012;15:245–51.PubMedCrossRef

30.

Brierley JD, Gospodarowicz MK, Wittekind C, editors. International Union Against Cancer (UICC): TNM classification of malignant tumors. 8th ed. Chichester: Wiley; 2016.

31.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

32.

Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, et al. Evaluation of prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy followed by surgery. World J Surg. 2018;42:1496–505.PubMedCrossRef

33.

Hamai Y, Hihara J, Emi M, Furukawa T, Ibuki Y, Yamakita I, et al. Effects of neoadjuvant chemoradiotherapy on pathological TNM stage and their prognostic significance for surgically treated esophageal squamous cell carcinoma. Anticancer Res. 2017;37:5639–46.PubMed

34.

Emi M, Hihara J, Hamai Y, Aoki Y, Okada M, Kenjo M, et al. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol. 2012;69:1499–505.PubMedCrossRef

35.

Hamai Y, Hihara J, Emi M, Murakami Y, Kenjo M, Nagata Y, et al. Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer. Ann Thorac Surg. 2015;99:1887–93.PubMedCrossRef

36.

Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, et al. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2018;59:616–24.PubMedPubMedCentralCrossRef

37.

Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.PubMedCrossRef

38.

Nemoto K, Matsushita H, Ogawa Y, Takeda K, Takahashi C, Britton KR, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol. 2003;26:46–9.PubMedCrossRef

39.

Nakamura T. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.PubMedCrossRef

40.

Hamai Y. Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma. World J Surg. 2017;42:2190–8.CrossRef

41.

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.PubMedCrossRef

42.

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.PubMedCrossRef

Title: The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma
Authors: Manato Ohsawa
Yoichi Hamai
Manabu Emi
Yuta Ibuki
Tomoaki Kurokawa
Toru Yoshikawa
Ryosuke Hirohata
Nao Kitasaki
Morihito Okada
Publication date: 25-05-2023
Publisher: Springer Nature Singapore
Keywords: Metastasis
Esophageal Cancer
Esophageal Cancer
Radiotherapy
Cytostatic Therapy
Published in: Surgery Today / Issue 1/2024
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-023-02702-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Impact of the coronavirus disease 2019 pandemic on gastric and colorectal cancer surgeries: a multicenter epidemiologic study from the Kinki region of Japan

Clinical significance of colonoscopy before laparoscopic bariatric/metabolic surgery in Japanese patients

A simple nomogram for predicting occult lymph node metastasis of non-small cell lung cancer from preoperative computed tomography findings, including the volume-doubling time

Acknowledgment to reviewers

The impact of staple transection of the dorsal venous complex and urethra on intraoperative blood loss in cooperative laparoscopic and transperineal endoscopic pelvic exenteration

Oncoplastic breast surgery to prevent “Bird’s beak” deformity in the breast: a comparative retrospective study